Mollifeye (Chloramphenicol)

Chloramphenicol binds to the 50S ribosomal subunit of susceptible bacteria, blocking the peptidyl transferase step of protein synthesis. This stops the formation of new proteins, halting bacterial replication and allowing the immune system to clear the infection.

The dosing regimen for Mollifeye is determined by the prescribing clinician based on the type and severity of the infection, patient age and ocular condition. Typical regimens involve one to several drops per eye at prescribed intervals, but exact instructions must come from a qualified healthcare professional.

Safety data for ophthalmic chloramphenicol during pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and consider alternative treatments when appropriate. Pregnant or nursing patients should discuss use with their physician.

To request Mollifeye, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mollifeye (chloramphenicol) offers a broad spectrum of activity against many Gram‑positive and Gram‑negative ocular pathogens and is bacteriostatic. Compared with fluoroquinolone eye drops, it may have a lower risk of resistance development but carries rare systemic toxicity concerns, making patient selection important.

Mollifeye should be stored at room temperature, protected from direct light and moisture. Keep the container tightly closed and retain it in its original packaging until use. Do not freeze the product, and discard any solution that appears discolored or contaminated.

Mollifeye is applied topically to the eye as directed by the prescriber. Typically, the recommended number of drops is placed into the conjunctival sac of the affected eye(s) at the prescribed interval, avoiding contact with the tip of the bottle to maintain sterility.

Serious adverse events, although rare, include allergic contact dermatitis with swelling, corneal epithelial toxicity that can lead to ulceration, and systemic bone‑marrow suppression such as aplastic anemia. Patients should be instructed to seek immediate medical attention if they experience severe eye pain, vision changes or systemic symptoms.

Mollifeye is contraindicated in individuals with a known hypersensitivity to chloramphenicol or any excipients in the formulation. It should also be avoided in patients with pre‑existing severe bone‑marrow disorders and used with caution in pregnant or nursing women until a risk‑benefit assessment is performed.